Related Experiment Video
Updated: May 12, 2026

Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
Glycoprotein IIb/IIIa inhibitors
1Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA. lincofa@ccf.org
The role of glycoprotein (GP) IIb/IIIa inhibitors in interventional cardiology continues to evolve. This review focuses on contemporary research to evaluate the appropriate context for the use of GP IIb/IIIa inhibitors.
The role of glycoprotein (GP) IIb/IIIa inhibitors in interventional cardiology continues to evolve. This review focuses on contemporary research to evaluate the appropriate context for the use of GP IIb/IIIa inhibitors.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Inhibitors of Viral Protein Synthesis
Dipeptidyl Peptidase 4 Inhibitors
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...

